Investigating the metabolic capabilities of Mycobacterium tuberculosis H37Rv using the in silico strain iNJ661 and proposing alternative drug targets

<p>Abstract</p> <p>Background:</p> <p><it>Mycobacterium tuberculosis </it>continues to be a major pathogen in the third world, killing almost 2 million people a year by the most recent estimates. Even in industrialized countries, the emergence of multi-drug resistant (MDR) strains of tuberculosis hails the need to develop additional medications for treatment. Many of the drugs used for treatment of tuberculosis target metabolic enzymes. Genome-scale models can be used for analysis, discovery, and as hypothesis generating tools, which will hopefully assist the rational drug development process. These models need to be able to assimilate data from large datasets and analyze them.</p> <p>Results:</p> <p>We completed a bottom up reconstruction of the metabolic network of <it>Mycobacterium tuberculosis </it>H37Rv. This functional <it>in silico </it>bacterium, <it>iNJ</it>661, contains 661 genes and 939 reactions and can produce many of the complex compounds characteristic to tuberculosis, such as mycolic acids and mycocerosates. We grew this bacterium <it>in silico </it>on various media, analyzed the model in the context of multiple high-throughput data sets, and finally we analyzed the network in an 'unbiased' manner by calculating the Hard Coupled Reaction (HCR) sets, groups of reactions that are forced to operate in unison due to mass conservation and connectivity constraints.</p> <p>Conclusion:</p> <p>Although we observed growth rates comparable to experimental observations (doubling times ranging from about 12 to 24 hours) in different media, comparisons of gene essentiality with experimental data were less encouraging (generally about 55%). The reasons for the often conflicting results were multi-fold, including gene expression variability under different conditions and lack of complete biological knowledge. Some of the inconsistencies between <it>in vitro </it>and <it>in silico </it>or <it>in vivo </it>and <it>in silico </it>results highlight specific loci that are worth further experimental investigations. Finally, by considering the HCR sets in the context of known drug targets for tuberculosis treatment we proposed new alternative, but equivalent drug targets.</p

Modeling metabolism of Mycobacterium tuberculosis

Approximately one-fourth of the Mycobacterium tuberculosis (Mtb) genome contains genes that encode enzymes directly involved in its metabolism. These enzymes represent potential drug targets that can be systematically probed with constraint based (CB) models through the prediction of genes essential (or the combination thereof) for the pathogen to grow. However, gene essentiality depends on the growth conditions and, so far, no in vitro model precisely mimics the host at the different stages of mycobacterial infection, limiting model predictions. A first step in creating such a model is a thoroughly curated and extended genome-scale CB metabolic model of Mtb metabolism. The history of genome-scale CB models of Mtb metabolism up to model sMtb are discussed and sMtb is quantitatively validated using 13C measurements. The human pathogen Mtb has the capacity to escape eradication by professional phagocytes. During infection, Mtb resists the harsh environment of phagosomes and actively manipulates macrophages and dendritic cells to ensure prolonged intracellular survival. In contrast to many other intracellular pathogens, it has remained difficult to capture the transcriptome of mycobacteria during infection due to an unfavorable host-to-pathogen ratio. The human macrophage-like cell line THP-1 was infected with the attenuated Mtb surrogate Mycobacterium bovis Bacillus Calmette–Guérin (M. bovis BCG). Mycobacterial RNA was up to 1000-fold underrepresented in total RNA preparations of infected host cells. By combining microbial enrichment with specific ribosomal RNA depletion the transcriptional responses of host and pathogen during infection were simultaneously analyzed using dual RNA sequencing. Mycobacterial pathways for cholesterol degradation and iron acquisition are upregulated during infection. In addition, genes involved in the methylcitrate cycle, aspartate metabolism and recycling of mycolic acids are induced. In response to M. bovis BCG infection, host cells upregulate de novo cholesterol biosynthesis presumably to compensate for the loss of this metabolite by bacterial catabolism. By systematically probing the metabolic network underpinning sMtb, the reactions that are essential for Mtb are identified. A majority of these reactions are catalyzed by enzymes and thus represent candidate drug targets to fight an Mtb infection. Modeling the behavior of the bacteria during infection requires knowledge of the so-called biomass reaction that represents bacterial biomass composition. This composition varies in different environments or bacterial growth phases. Accurate modeling of all fluxes through metabolism under a given condition at a moment in time, the so called metabolic state, requires a precise description of the biomass reaction for the described condition. The transcript abundance data obtained by dual RNA sequencing was used to develop a straightforward and systematic method to obtain a condition-specific biomass reaction for Mtb during in vitro growth and during infection of its host. The method described herein is virtually free of any pre-set assumptions on uptake rates of nutrients, making it suitable for exploring environments with limited accessibility. The condition-specific biomass reaction represents the 'metabolic objective' of Mtb in a given environment (in-host growth and growth on defined medium) at a specific time point, and as such allows modeling the bacterial metabolic state in these environments. Five different biomass reactions were used predict nutrient uptake rates and gene essentiality. Predictions were subsequently compared to available experimental data. Nutrient uptake can accurately be predicted, but accurate gene essentiality predictions remain difficult to obtain. By combining sMtb and a model of human metabolism, model sMtb-RECON was developed and used to predict the metabolic state of Mtb during infection of the host. Amino acids are predicted to be used for energy production as well as biomass formation. Subsequently the effect of increasing dosages of drugs, targeting metabolism, on the metabolic state of the pathogen was assessed and resulting metabolic adaptations and flux rerouting through various pathways is predicted. In particular, the TCA cycle becomes more important upon drug application, as well as alanine, aspartate, glutamate, proline, arginine and porphyrin metabolism, while glycine, serine and threonine metabolism become less important for survival. Notably, an effect of eight out of eleven metabolically active drugs could be recreated and two major profiles of the metabolic state were predicted. The profiles of the metabolic states of Mtb affected by the drugs BTZ043, cycloserine and its derivative terizidone, ethambutol, ethionamide, propionamide, and isoniazid were very similar, while TMC207 is predicted to have quite a different effect on metabolism as it inhibits ATP synthase and therefore indirectly interferes with a multitude of metabolic pathways.</p

High quality genome-scale metabolic network reconstruction of mycobacterium tuberculosis and comparison with human metabolic network: application for drug targets identification

Mycobacterium tuberculosis (Mtb), a pathogenic bacterium, is the causative agent in the vast majority of human tuberculosis (TB) cases. Nearly one-third of the world’s population has been affected by TB and annually two million deaths result from the disease. Because of the high cost of medication for a long term treatment with multiple drugs and the increase of multidrug-resistant Mtb strains, faster-acting drugs and more effective vaccines are urgently demanded. Several metabolic pathways of Mtb are attractive for identifying novel drug targets against TB. Hence, a high quality genome-scale metabolic network of Mtb (HQMtb) was reconstructed to investigate its whole metabolism and explore for new drug targets. The HQMtb metabolic network was constructed using an unbiased approach by extracting gene annotation information from various databases and consolidating the data with information from literature. The HQMtb consists of 686 genes, 607 intracellular reactions, 734 metabolites and 471 E.C. numbers, 27 of which are incomplete. The HQMtb was compared with two recently published Mtb metabolic models, GSMN-TB by Beste et al. and iNJ661 model by Jamshidi and Palsson. Due to the different reconstruction methods used, the three models have different characteristics. The 68 new genes and 80 new E.C. numbers were found only in the HQMtb and resulting in approximately 52 new metabolic reactions located in various metabolic pathways, for example biosynthesis of steroid, fatty acid metabolism, and TCA cycle. Through a comparison of HQMtb with a previously published human metabolic network (EHMN) in terms of protein signatures, 42 Mtb metabolic genes were proposed as new drug targets based on two criteria: (a) their protein functional sites do not match with any human protein functional sites; (b) they are essential genes. Interestingly, 13 of them are found in a list of current validated drug targets. Among all proposed drug targets, Rv0189c, Rv3001c and Rv3607c are of interest to be tested in the laboratory because they were also proposed as drug target candidates from two research groups using different methods

Development and analysis of an in vivo-compatible metabolic network of Mycobacterium tuberculosis

<p>Abstract</p> <p>Background</p> <p>During infection, <it>Mycobacterium tuberculosis </it>confronts a generally hostile and nutrient-poor <it>in vivo </it>host environment. Existing models and analyses of <it>M. tuberculosis </it>metabolic networks are able to reproduce experimentally measured cellular growth rates and identify genes required for growth in a range of different <it>in vitro </it>media. However, these models, under <it>in vitro </it>conditions, do not provide an adequate description of the metabolic processes required by the pathogen to infect and persist in a host.</p> <p>Results</p> <p>To better account for the metabolic activity of <it>M. tuberculosis </it>in the host environment, we developed a set of procedures to systematically modify an existing <it>in vitro </it>metabolic network by enhancing the agreement between calculated and <it>in vivo-</it>measured gene essentiality data. After our modifications, the new <it>in vivo </it>network contained 663 genes, 838 metabolites, and 1,049 reactions and had a significantly increased sensitivity (0.81) in predicted gene essentiality than the <it>in vitro </it>network (0.31). We verified the modifications generated from the purely computational analysis through a review of the literature and found, for example, that, as the analysis suggested, lipids are used as the main source for carbon metabolism and oxygen must be available for the pathogen under <it>in vivo </it>conditions. Moreover, we used the developed <it>in vivo </it>network to predict the effects of double-gene deletions on <it>M. tuberculosis </it>growth in the host environment, explore metabolic adaptations to life in an acidic environment, highlight the importance of different enzymes in the tricarboxylic acid-cycle under different limiting nutrient conditions, investigate the effects of inhibiting multiple reactions, and look at the importance of both aerobic and anaerobic cellular respiration during infection.</p> <p>Conclusions</p> <p>The network modifications we implemented suggest a distinctive set of metabolic conditions and requirements faced by <it>M. tuberculosis </it>during host infection compared with <it>in vitro </it>growth. Likewise, the double-gene deletion calculations highlight the importance of specific metabolic pathways used by the pathogen in the host environment. The newly constructed network provides a quantitative model to study the metabolism and associated drug targets of <it>M. tuberculosis </it>under <it>in vivo </it>conditions.</p

targetTB: A target identification pipeline for Mycobacterium tuberculosis through an interactome, reactome and genome-scale structural analysis

<p>Abstract</p> <p>Background</p> <p>Tuberculosis still remains one of the largest killer infectious diseases, warranting the identification of newer targets and drugs. Identification and validation of appropriate targets for designing drugs are critical steps in drug discovery, which are at present major bottle-necks. A majority of drugs in current clinical use for many diseases have been designed without the knowledge of the targets, perhaps because standard methodologies to identify such targets in a high-throughput fashion do not really exist. With different kinds of 'omics' data that are now available, computational approaches can be powerful means of obtaining short-lists of possible targets for further experimental validation.</p> <p>Results</p> <p>We report a comprehensive <it>in silico </it>target identification pipeline, targetTB, for <it>Mycobacterium tuberculosis</it>. The pipeline incorporates a network analysis of the protein-protein interactome, a flux balance analysis of the reactome, experimentally derived phenotype essentiality data, sequence analyses and a structural assessment of targetability, using novel algorithms recently developed by us. Using flux balance analysis and network analysis, proteins critical for survival of <it>M. tuberculosis </it>are first identified, followed by comparative genomics with the host, finally incorporating a novel structural analysis of the binding sites to assess the feasibility of a protein as a target. Further analyses include correlation with expression data and non-similarity to gut flora proteins as well as 'anti-targets' in the host, leading to the identification of 451 high-confidence targets. Through phylogenetic profiling against 228 pathogen genomes, shortlisted targets have been further explored to identify broad-spectrum antibiotic targets, while also identifying those specific to tuberculosis. Targets that address mycobacterial persistence and drug resistance mechanisms are also analysed.</p> <p>Conclusion</p> <p>The pipeline developed provides rational schema for drug target identification that are likely to have high rates of success, which is expected to save enormous amounts of money, resources and time in the drug discovery process. A thorough comparison with previously suggested targets in the literature demonstrates the usefulness of the integrated approach used in our study, highlighting the importance of systems-level analyses in particular. The method has the potential to be used as a general strategy for target identification and validation and hence significantly impact most drug discovery programmes.</p

Metabolic modeling of mycobacterium tuberculosis through the integration of large-scale genomics datasets

Thesis (Ph. D.)--Boston UniversityMycobacterium tuberculosis (MTB) is the bacterium that is the causal agent of tuberculosis. MTB is estimated to infect one-third of the world's population. The emergence of multi drug-resistant and extensively drug-resistant strains of the bacterium are becoming a larger threat to global health as they decrease the efficacy of current treatments and make the disease more fatal. These factors combine to make MTB an interesting target for study with novel systems biology approaches. Genome-scale metabolic models have emerged as important platforms for the analysis of datasets that describe highly-interconnected biological processes. We have the first comprehensive profiling of mRNA, proteins, metabolites, and lipids in MTB during an in vitro model of infection that includes a time course of induced hypoxia andre-aeration. Hypoxia and reaeration are important cues during infection of the human host and act to model the environment seen in the host. We use genome-scale metabolic modeling methods to integrate these data with our metabolic model will allow us to generate experimentally testable predictions about metabolic adaptations that occur in response to experimental perturbations that represent an in vitro model of important environmental cues present during infection, dormancy, and re-activation in the human host

Analysis of complex metabolic behavior through pathway decomposition

<p>Abstract</p> <p>Background</p> <p>Understanding complex systems through decomposition into simple interacting components is a pervasive paradigm throughout modern science and engineering. For cellular metabolism, complexity can be reduced by decomposition into pathways with particular biochemical functions, and the concept of elementary flux modes provides a systematic way for organizing metabolic networks into such pathways. While decomposition using elementary flux modes has proven to be a powerful tool for understanding and manipulating cellular metabolism, its utility, however, is severely limited since the number of modes in a network increases exponentially with its size.</p> <p>Results</p> <p>Here, we present a new method for decomposition of metabolic flux distributions into elementary flux modes. Our method can easily operate on large, genome-scale networks since it does not require all relevant modes of the metabolic network to be generated. We illustrate the utility of our method for metabolic engineering of <it>Escherichia coli </it>and for understanding the survival of <it>Mycobacterium tuberculosis </it>(MTB) during infection.</p> <p>Conclusions</p> <p>Our method can achieve computational time improvements exceeding 2000-fold and requires only several seconds to generate elementary mode decompositions on genome-scale networks. These improvements arise from not having to generate all relevant elementary modes prior to initiating the decomposition. The decompositions from our method are useful for understanding complex flux distributions and debugging genome-scale models.</p

Identification of Functional Differences in Metabolic Networks Using Comparative Genomics and Constraint-Based Models

Genome-scale network reconstructions are useful tools for understanding cellular metabolism, and comparisons of such reconstructions can provide insight into metabolic differences between organisms. Recent efforts toward comparing genome-scale models have focused primarily on aligning metabolic networks at the reaction level and then looking at differences and similarities in reaction and gene content. However, these reaction comparison approaches are time-consuming and do not identify the effect network differences have on the functional states of the network. We have developed a bilevel mixed-integer programming approach, CONGA, to identify functional differences between metabolic networks by comparing network reconstructions aligned at the gene level. We first identify orthologous genes across two reconstructions and then use CONGA to identify conditions under which differences in gene content give rise to differences in metabolic capabilities. By seeking genes whose deletion in one or both models disproportionately changes flux through a selected reaction (e.g., growth or by-product secretion) in one model over another, we are able to identify structural metabolic network differences enabling unique metabolic capabilities. Using CONGA, we explore functional differences between two metabolic reconstructions of Escherichia coli and identify a set of reactions responsible for chemical production differences between the two models. We also use this approach to aid in the development of a genome-scale model of Synechococcus sp. PCC 7002. Finally, we propose potential antimicrobial targets in Mycobacterium tuberculosis and Staphylococcus aureus based on differences in their metabolic capabilities. Through these examples, we demonstrate that a gene-centric approach to comparing metabolic networks allows for a rapid comparison of metabolic models at a functional level. Using CONGA, we can identify differences in reaction and gene content which give rise to different functional predictions. Because CONGA provides a general framework, it can be applied to find functional differences across models and biological systems beyond those presented here